0R2M Stock Overview
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 2/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Regeneron Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$897.29 |
| 52 Week High | US$998.57 |
| 52 Week Low | US$689.00 |
| Beta | 0.14 |
| 1 Month Change | -6.84% |
| 3 Month Change | -4.03% |
| 1 Year Change | 12.14% |
| 3 Year Change | 83.24% |
| 5 Year Change | 163.11% |
| Change since IPO | 146.24% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0R2M | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | -0.7% | -2.3% | -0.7% |
| 1Y | 12.1% | -29.4% | -1.8% |
Return vs Industry: 0R2M exceeded the UK Biotechs industry which returned -29.4% over the past year.
Return vs Market: 0R2M exceeded the UK Market which returned -1.8% over the past year.
Price Volatility
| 0R2M volatility | |
|---|---|
| 0R2M Average Weekly Movement | 2.1% |
| Biotechs Industry Average Movement | 7.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 11.5% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0R2M has not had significant price volatility in the past 3 months.
Volatility Over Time: 0R2M's weekly volatility (2%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1988 | 13,450 | Leonard Schleifer | www.regeneron.com |
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company’s products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults.
Regeneron Pharmaceuticals, Inc. Fundamentals Summary
| 0R2M fundamental statistics | |
|---|---|
| Market cap | US$96.07b |
| Earnings (TTM) | US$3.95b |
| Revenue (TTM) | US$13.12b |
24.3x
P/E Ratio7.3x
P/S RatioIs 0R2M overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0R2M income statement (TTM) | |
|---|---|
| Revenue | US$13.12b |
| Cost of Revenue | US$6.25b |
| Gross Profit | US$6.86b |
| Other Expenses | US$2.91b |
| Earnings | US$3.95b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 02, 2024
| Earnings per share (EPS) | 36.79 |
| Gross Margin | 52.32% |
| Net Profit Margin | 30.14% |
| Debt/Equity Ratio | 7.6% |
How did 0R2M perform over the long term?
See historical performance and comparison